2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：1883650-95-0 Product Name：CDDO-3P-Im Synonyms：CDDO-3-P-Im;CDDO-3P-Im;AMY16850 EINEC: Molecular Formula：C39H46N4O3 Molecular Weight：618.8075
Target:
In Vivo
CDDO-3P-Im is more stable than CDDO-Im in pharmacokinetic studies[1]. CDDO-3P-Im significantly elevates heme oxygenase-1 (HO-1) and quinone reductase (NQO1) mRNA and protein levels in various mouse tissues in vivo[1]. CDDO-3P-Im (50-200 mg/kg; diet; for 16 weeks) decreases the number, the size and the severity of tumors in A/J mice[1]. Animal Model: Seven week-old female A/J mice[1] Dosage: 50 mg/kg, 200 mg/kg Administration: Diet; for 16 weeks Result: Decreased the number, the size and the severity of tumors.
In Vitro
CDDO-3P-Im (30-100 nM; 4 days) induces differentiation of U937 cells at 30 nM[1]. CDDO-3P-Im suppresses NO production in RAW264.7 cells with an IC50 of 4.3 nM[1]. Apoptosis Analysis[1] Cell Line: U937 cells Concentration: 30 nM, 100 nM Incubation Time: 4 days Result: Induced differentiation of U937 cells at 30 nM.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Cao M , et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharmacol Res. 2015 Oct;100:135-47.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
